Polypeptide, pharmaceutical composition and preparation method of pharmaceutical composition

A technology of pharmaceutical compounds and compositions, applied in the field of polypeptides and a pharmaceutical composition and its preparation, can solve problems such as good drug loading effect, and achieve good drug loading effect, good stability, and good biocompatibility

Active Publication Date: 2015-03-25
THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to overcome the defects that the existing nano-drug carriers cannot achieve good drug-loading effect, moderate drug release rate, good stability and good biocompatibility at the same time, and provide a drug-loading drug that can simultaneously achieve good drug-loading effect and drug release rate. Moderate, stable and biocompatible peptide self-assembled nano drug carrier

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide, pharmaceutical composition and preparation method of pharmaceutical composition
  • Polypeptide, pharmaceutical composition and preparation method of pharmaceutical composition
  • Polypeptide, pharmaceutical composition and preparation method of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0030] The present invention also provides a preparation method of a pharmaceutical composition, which comprises contacting a solution of a pharmaceutical compound with the polypeptide represented by the above-mentioned formula (1) of the present invention to obtain a contacted material.

[0031] In the present invention, there is no particular limitation on the above-mentioned contacting method, and it can be various methods routinely used in the art to prepare nano-pharmaceutical compositions, as long as the drug compound solution can be combined with the polypeptide represented by formula (1) It is enough to form a pharmaceutical composition. Preferably, the above-mentioned conditions for contacting the drug compound solution with the polypeptide represented by the formula (1) of the present invention may include: a pH value of 6-8, a temperature of 4-45°C, and a time of 12 -48 hours. Preferably, the contacting conditions include: a pH value of 6.5-7.5, a temperature of 20...

Embodiment approach

[0032] According to a preferred embodiment of the present invention, the preparation method of the pharmaceutical composition comprises mixing the pharmaceutical compound solution with the polypeptide represented by the formula (1) of the present invention, and then dialyzing with a dialysis bag without being coated Buried drug compounds are eliminated during this process, thereby obtaining a pharmaceutical composition. As the dialysis bag, for example, a dialysis bag with a molecular weight cut off of 1 kDa can be used. The dialysis is preferably performed in a phosphate buffer (eg, pH value is 7.4, 150 mmol / L), more preferably the phosphate buffer is changed every 3-5 hours, and the dialysis is performed for 20-30 hours.

[0033] According to a preparation method of a pharmaceutical composition provided by the present invention, the dosage of the pharmaceutical compound is 0.05-1 part by weight relative to the polypeptide represented by the above formula (1). Preferably, th...

preparation example 1

[0050] This preparation example is used to synthesize the polypeptide provided by the present invention.

[0051] According to the method provided in the literature (Lihong Liu et al., Nature nanotechnology, 2009, Vol4, July), synthesize the polypeptide shown in formula (1), the difference is that m of the polypeptide synthesized in this preparation example is 1, and n is 9. The C-terminal amino acid of the polypeptide is arginine, and the polypeptide sequence does not contain tyrosine. Identified by mass spectrometry (time-of-flight mass spectrometry, MALDI-TOF, BRUKER, microflex.LRF, USA), its molecular weight is 1878Da, which is completely consistent with the molecular weight of the polypeptide (m is 1, n is 9) shown in formula (1), named The polypeptide represented by the formula (1) (m is 1, n is 9) is AP.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention provides a polypeptide. The polypeptide has a structure as shown in a formula (1) described in the specification, wherein m is an integer from 1 to 3, and n is an integer from 3 to 20. The invention further provides a pharmaceutical composition and a preparation method thereof. The preparation method of the pharmaceutical composition comprises the following steps: enabling a medicine compound solution to contact with the polypeptide disclosed by the invention to obtain a contacted material. The pharmaceutical composition obtained by the preparation method of the pharmaceutical composition disclosed by the invention can simultaneously realize good medicine carrying effects, moderate medicine release speed, good stability and good biocompatibility.

Description

technical field [0001] The present invention relates to the field of pharmaceutical preparations, in particular to a polypeptide, a pharmaceutical composition and a preparation method thereof. Background technique [0002] In recent years, the research and development of nano-drug carriers has received extensive attention. Nano-drug carriers have many advantages, such as: nanoparticles are easy to prepare, modified and processed with good controllability, and can protect drugs, genes or functional molecules from degradation by the body or some enzymes, etc. Some nanoparticles, while acting as "carriers", also have the function of immune adjuvants. [0003] Molecular self-assembly is the use of molecular recognition between molecules or between a certain segment of a molecule and another segment, through non-covalent weak interactions such as hydrogen bonds, van der Waals forces, electrostatic forces, hydrophobic interactions, and π-π stacking interactions. The process by w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K5/10C07K7/06C07K7/08C07K14/00A61K47/18A61K47/42A61K45/00A61P35/00A61K31/704A61K31/337A61K31/4745
Inventor 赵颖聂广军季天骄赵瑞芳郎佳妍
Owner THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap